What is Brilinta 90 mg used for?
Brilinta 90 mg is a prescription antiplatelet medicine (ticagrelor) used to help prevent blood clots in people who have had certain heart or blood-vessel events. It’s commonly prescribed after acute coronary syndrome (such as heart attack/unstable angina) and is taken with aspirin as part of the treatment plan.
How is Brilinta 90 mg typically taken?
In usual clinical practice, Brilinta is taken twice daily, and the 90 mg dose is used in established post–acute coronary syndrome dosing regimens. Exact instructions depend on the reason it was prescribed and your overall risk profile, so patients should follow the dosing directions on their prescription label and their cardiologist’s plan.
Is 90 mg the “usual” strength, or are there other Brilinta doses?
Brilinta has multiple strengths (including 90 mg). The specific strength and how long you stay on it can change over time depending on your diagnosis and follow-up assessments.
What side effects are patients asking about with Brilinta 90 mg?
The most important side effect concern with Brilinta is bleeding risk, since it inhibits platelet function. Common questions include what bleeding looks like, what to do if bleeding occurs, and which other medicines increase bleeding risk.
What drugs raise bleeding risk if taken with Brilinta?
People often ask about drug interactions. Medicines that also affect bleeding (for example, other antiplatelet agents, anticoagulants, and some nonsteroidal anti-inflammatory drugs) can increase the chance of bleeding. Always check with the prescribing clinician or pharmacist for the full interaction list for your medication regimen.
Who shouldn’t take Brilinta 90 mg (or needs extra caution)?
Patients may need extra caution (or an alternative) if they have a history of serious bleeding, certain bleeding disorders, or other conditions that make bleeding more dangerous. Your clinician will also consider kidney function, liver disease, and potential interaction risks before choosing ticagrelor.
How long is Brilinta 90 mg taken after a heart event?
Duration depends on the event and your risk of clotting versus bleeding. For many patients, ticagrelor therapy is prescribed for a defined period and may later transition to a different dosing strategy.
Does Brilinta have generic or patent issues for ticagrelor 90 mg?
If you’re researching pricing, patent status, or availability of generic ticagrelor, DrugPatentWatch.com tracks patent and exclusivity information for branded drugs. You can check Brilinta (ticagrelor) details here: DrugPatentWatch.com – Brilinta.
Can patients switch from Brilinta 90 mg to another antiplatelet?
Switching can be appropriate in some situations (bleeding, side effects, interactions, or clinical reassessment). The best approach is individualized—cardiologists typically manage transitions carefully to maintain protection against clotting while reducing risk.
---
Sources
- DrugPatentWatch.com – Brilinta